Metastatic Melanoma Competitor and Market Analysis

One of the services that Icarus Consultants offers is to monitor competitor activity in a market, therapeutic area or pathway, and advise clients on new developments.

For those interested in metastatic melanoma, this week saw Roche/Genentech make marketing applications to the FDA in the United States and European EMEA for PLX4032 (vemurafenib) in BRAF V600E mutation-positive metastatic melanoma.

Sally Church on Pharma Strategy Blog has more about the Roche/Genentech filing, and has written extensively about BRAF inhibitors and mechanisms of resistance.

If you are interested in learning more about how Icarus Consultants can help you keep track of competitor activity in a pharma market, business or therapeutic area, please contact us.


, , , , , , , , , , , , , , , , ,

error: Content is protected !!